Beam Therapeutics Inc (BEAM)
Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
BEAM SEC Filing Email Alerts Service
| Company Name: |
Beam Therapeutics Inc |
| Website: |
www.beamtx.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding BEAM: |
40 |
| Total Market Value Held by ETFs: |
$421.46M |
| Total Market Capitalization: |
$1.75B |
| % of Market Cap. Held by ETFs: |
24.14% |
|
|
April 30, 2024 • 11:33 AM Eastern
Buy (3.07 out of 4)
34th percentile
|
|
Free BEAM Email Alerts:
